CLASS II ONGOING Device recall · Reported 21 Jan 2026 · FDA Enforcement Report

Asserachrom HPIA recalled by Diagnostica Stago

Diagnostica Stago is recalling Asserachrom HPIA, distributed nationwide in the US. The recall was initiated on 15 Dec 2025 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesReference Number: 00615. UDI: (01)03607450006155(11)240531(17)260531(10)271288(241)00615. Lot Number: 271288.
Quantity recalled438 units

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-1084-2026
FDA event ID
98163
Recalling firm
Diagnostica Stago, Parsippany, NJ
Classification
Class II
Status
Ongoing
Recall initiated
15 Dec 2025
FDA classified
14 Jan 2026
Reported
21 Jan 2026
Type
Voluntary: Firm initiated
Customers notified by
E-Mail
Reason category
Device Malfunction

Timeline

15 Dec 2025Recall initiated by company
14 Jan 2026Classified by FDA+30 days
21 Jan 2026Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Potential for defect for Asserachrom HPIA lot 271288, which can affect every well in the impacted strip and produce negative results.

Device recalls are issued when a component, software or design fault could cause the device to fail or give wrong readings. Many are corrections applied in the field rather than physical returns.

Product as listed by the FDA

Asserachrom HPIA. Model/Catalog Number: 00615. The Asserachrom HPIA kit is intended for the qualitative detection in plasma or serum of the anti-heparin-platelet factor 4 (PF4) antibodies generated during the type II heparin-induced thrombocytopenia (HIT type II) by ELISA.

Where it was distributed

Worldwide - US Nationwide distribution in the states of AL, CA, FL, GA, HI, IA, MA, MI, NJ, NV, NY, OH, TN, WI and the countries of Belgium, Canada, Denmark, Algeria, Spain, Finland, France, Great Britain, Italy, Lebanon, Saudi Arabia, Uganda.

Nationwide AlabamaCaliforniaFloridaGeorgiaHawaiiIowaMassachusettsMichiganNew JerseyNevadaNew YorkOhioTennesseeWisconsin

Questions about this recall

Why was it recalled?

Potential for defect for Asserachrom HPIA lot 271288, which can affect every well in the impacted strip and produce negative results.

Which lots are affected?

Reference Number: 00615. UDI: (01)03607450006155(11)240531(17)260531(10)271288(241)00615. Lot Number: 271288.

Where was it sold?

Worldwide - US Nationwide distribution in the states of AL, CA, FL, GA, HI, IA, MA, MI, NJ, NV, NY, OH, TN, WI and the countries of Belgium, Canada, Denmark, Algeria, Spain, Finland, France, Great Britain, Italy, Lebanon, Saudi Arabia, Uganda.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Diagnostica Stago

All 27

Other Other Medical Devices recalls

All 13,908